SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-000176
Filing Date
2023-01-05
Accepted
2023-01-05 07:30:43
Documents
15
Period of Report
2023-01-04
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K labp-20230104.htm   iXBRL 8-K 69280
2 EX-4.1 labp-ex4_1.htm EX-4.1 171784
3 EX-10.1 labp-ex10_1.htm EX-10.1 278758
4 EX-99.1 labp-ex99_1.htm EX-99.1 18851
  Complete submission text file 0000950170-23-000176.txt   726183

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT labp-20230104.xsd EX-101.SCH 2478
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT labp-20230104_lab.xml EX-101.LAB 13350
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT labp-20230104_pre.xml EX-101.PRE 9846
9 EXTRACTED XBRL INSTANCE DOCUMENT labp-20230104_htm.xml XML 4696
Mailing Address 1800 KRAFT DRIVE, SUITE 216 BLACKSBURG VA 24060
Business Address 1800 KRAFT DRIVE, SUITE 216 BLACKSBURG VA 24060 540-818-2844
Landos Biopharma, Inc. (Filer) CIK: 0001785345 (see all company filings)

IRS No.: 815085535 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39971 | Film No.: 23509729
SIC: 2834 Pharmaceutical Preparations